Literature DB >> 6381332

Dehiscence of aortic valve prostheses: analysis of a ten-year experience.

G Rizzoli, R Russo, S Valente, A Mazzucco, C Valfré, T Brumana, G Aru, M Rubino, F Rocco, V Gallucci.   

Abstract

Up to the end of 1982, reoperation for dehiscence of an aortic prosthesis was necessary in 5% of patients operated on for primary aortic valve replacement in the previous decade at the University of Padova Cardiac Surgery Center. This complication occurred early (median time to diagnosis 4 months) and was associated with an elevated 30-day operative mortality (27%, 70% CL 19-37%). This is probably (P = 0.09) related to preoperative heart failure. The follow-up of the traced surviving patients (92%) indicates a continuing poor prognosis with a 6-year survival rate of only 13.5% (70% CL 5.0-30%). All the events were cardiac related and directly or indirectly connected with the persistence or recurrence of dehiscence that was observed in 72% of the cases. In the face of these results, a retrospective study has been performed to identify, on the basis of the available data, the subsets of patients more prone to develop this complication. Our results suggest that a significant increased risk (P less than 0.001) can be identified in patients presenting with bacterial endocarditis (12.2% rate), in patients with concomitant aneurysm of the ascending aorta (10.9%) and in patients with degenerative regurgitation or severe calcifications of their native valve, with rates of 7.0 and 6.0 respectively. In these situations particular care is required to avoid undue stress on the annular tissue. We also suggest the use of buttressed interrupted sutures.

Entities:  

Mesh:

Year:  1984        PMID: 6381332     DOI: 10.1016/0167-5273(84)90355-3

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  1 in total

1.  Unruptured aneurysm of the left sinus of Valsalva compressing the left main coronary artery: successful percutaneous treatment.

Authors:  P Hausinger; V Sasi; G Volford; M Bitay; G Bogáts; A Thury; A Palkó; T Forster; A Nemes
Journal:  Herz       Date:  2013-07-25       Impact factor: 1.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.